08 January 2020
Visiongain’s new report the Primary Cell Culture Market Report: Forecasts by Origin (Hematopoietic Cells, Skin Cells, Gastrointestinal Cells, Liver Cells, Lung Cells, Renal Cells, Muscle Cells, Other Cells), by Type (Human, Animal), by End User (Life Science Research Companies, Research Institutes), plus analysis of leading companies operating in the global primary cell culture market.
Fewer chances of mutations and modifications, reducing testing cost, growing production of regenerative medicines, rising research & development in biotechnology and increasing demand for stem cell therapy is expected to drive global primary cell culture market over the projected period. In 2019, global primary cell culture market revenue was valued at $779 million and is expected to reach $1.80 billion by 2029 at a CAGR of 8.7%. Other major factors driving the growth of primary cell culture market are growing prevalence of cancer and other chronic diseases all over the world. According to the National Cancer Institute, in 2018, more than 1.5 million new cases of cancer were diagnosed in the United States and more than 600k people died from cancer.
The drain of chronic diseases is rapidly increasing worldwide. According to the World Health Organization, in 2001, chronic diseases contributed approximately 60% of the 56.5 million total reported deaths in the world and approximately 46% of the global burden of disease. The proportion of the burden of chronic diseases is expected to increase to 57% by 2020. This, in turn, is expected to propel the primary cell culture industry over the coming years.
By region, North America dominated the global primary cell culture industry in 2019 and is expected to grow by virtue of technological advancement followed by well-developed healthcare infrastructure. Additionally, development and introduction of cell culture technologies coupled with increasing adoption of advanced therapies in Canada, the United States, and Mexico are expected to help market expansion over the coming years. Moreover, hectic lifestyle, increasing working hours, increasing working population, and consumer trends towards unhealthy foods has increased prevalence of chronic diseases in this region, which is expected to encourage primary cell culture industry over the projected period.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.
26 November 2020
Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.
25 November 2020
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth
24 November 2020
Increasing prevalence of cardiovascular diseases is increasing demand of biological imaging reagents for the diagnosis and treatment of cardiovascular diseases due to this reason increasing prevalence of cardiovascular diseases is acting as a driver for biological imaging reagent market.